Quantification, Microbial Contamination, Physico-chemical Stability of Repackaged Bevacizumab Stored Under Different Conditions

ISSN: 1873-4316 (Online)
ISSN: 1389-2010 (Print)


Volume 15, 12 Issues, 2014


Download PDF Flyer




Current Pharmaceutical Biotechnology

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 112th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Zeno Foldes-Papp
Visiting Professor of Medical Biochemistry
HELIOS Clinical Center of Emergency Medicine
Department for Internal Medicine
Alte-Koelner-Strasse 9
D-51688 Koeln-Wipperfuerth
Germany


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.511
5 - Year: 2.817

Quantification, Microbial Contamination, Physico-chemical Stability of Repackaged Bevacizumab Stored Under Different Conditions

Author(s): Leonarda Signorello, Stefania Pucciarelli, Giulia Bonacucina, Valeria Polzonetti, Marco Cespi, Diego R. Perinelli, Giovanni F. Palmieri, Riccardo Pettinari, Claudio Pettinari, Giovanni Fiorentini and Silvia Vincenzetti

Affiliation: School of School of Biosciences and Veterinary Medicine, University of Camerino, Via circonvallazione 93/95, 62024 Matelica (MC), Italy.

Abstract

In this work, the stability of Bevacizumab (Avastin®) repackaged in individual 1 mL single-use syringes and stored at different conditions was assessed. Bevacizumab repackaged in single-use syringes results from the off-label use of the drug as an intravitreal agent in the treatment of retinal diseases. Bevacizumab stability was assessed by assaying the anti-VEGF activity using an indirect ELISA method and a Dynamic Light Scattering study. The thermal stability of the drug was also studied by calorimetric analysis, aimed to evaluate thermodynamic parameters associated to the thermal unfolding process. Furthermore, microbiological and fungal tests on the Bevacizumab syringes were performed. As a result, a significant decrease of the anti-VEGF activity was detected when syringes were exposed to UV light at a temperature of 37°C. Under these conditions, the Dynamic Light Scattering study showed an increase of the average size of Bevacizumab; probably due to aggregation. In conclusion, Bevacizumab stability, when stored under different conditions, was assessed considering three different aspects: anti-VEGF activity, microbial contamination and physico-chemical properties. Bevacizumab was found to be stable, under sterile conditions, for 3 months at 4°C and for 7 days at room temperature, exposed to indirect light sources, while a brief exposure of the drug to direct UV radiation proved detrimental to drug stability.

Keywords: Anti-VEGF activity, Bevacizumab, Bevacizumab stability, calorimetric studies, dynamic light scattering, repackaged Bevacizumab, microbiological assay, immunoassay.

Download Free Rights and Permissions

  
  



Article Details

Volume: 15
Issue Number: 2
First Page: 113
Last Page: 119
Page Count: 7
DOI: 10.2174/1389201015666140619120834
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science